<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04648631</url>
  </required_header>
  <id_info>
    <org_study_id>20201035</org_study_id>
    <nct_id>NCT04648631</nct_id>
  </id_info>
  <brief_title>Hidradenitis Suppurativa (HS) Tunneling Wounds</brief_title>
  <official_title>The Microbiome of Hidradenitis Suppurativa (HS) Tunneling Wounds</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Miami</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Next Science LLC</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Miami</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to look at the change in the microbiome (bacterial composition)&#xD;
      of an HS tunneling wound and examine if treatment with an antibiofilm surfactant wound gel&#xD;
      (ABWG) (a topical medication that will fight bacteria attached to the surface of those&#xD;
      tunnels) changes the bacterial composition of the wounds.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 26, 2021</start_date>
  <completion_date type="Anticipated">March 1, 2023</completion_date>
  <primary_completion_date type="Anticipated">March 1, 2023</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in microbiome</measure>
    <time_frame>Baseline, 4 weeks</time_frame>
    <description>As measured by quantitative 16s rDNA Polymerase Chain Reaction for bacterial enumeration from punch biopsy samples.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in lesion severity as measured by HS-PGA</measure>
    <time_frame>Baseline, 4 weeks</time_frame>
    <description>HS Physician's Global Assessment (HS-PGA) Scale is a 6 point Likert scale from 0 (clear) to 5 (very severe)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in lesion severity as measured by the Hurley Stage</measure>
    <time_frame>Baseline, 4 weeks</time_frame>
    <description>The Hurley score is staged as: 1 (single or multiple abscesses without sinus tract formation or scarring); 2 (recurrent abscesses with one or more sinus tracts and scarring widely separated by normal skin); 3 (diffuse involvement with multiple sinus tracts and no intervening normal skin).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in pain as measured by VAS</measure>
    <time_frame>Baseline, 4 weeks</time_frame>
    <description>Visual Analog Scale (VAS) has a total score ranging from 0 to 10 with the higher score indicating greater pain.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change HS lesion erythema</measure>
    <time_frame>Baseline, 4 weeks</time_frame>
    <description>As measured the Clinician Erythema Assessment (CEA) scale. CEA scale ranges from 0 (clear) to 4 (severe).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in exudate</measure>
    <time_frame>Baseline, 4 weeks</time_frame>
    <description>Exudate will be evaluated using a 5 point Likert scale from 0 (Dry) to 4 (Leaking).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in range of motion</measure>
    <time_frame>Baseline, 4 weeks</time_frame>
    <description>As measured by a goniometer</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with decreased pain medication use</measure>
    <time_frame>4 weeks</time_frame>
    <description>Change in pain medication use will be reported as the number of participants that reports a decrease in the dose and/or frequency of pain medication use</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with escalated pain medication use</measure>
    <time_frame>4 weeks</time_frame>
    <description>Change in pain medication use will be reported as the number of participants that reports an escalation from using Non-steroidal Anti-inflammatory Drugs (NSAIDs)/acetaminophen to opioids</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in number of days of work/school lost</measure>
    <time_frame>Baseline, 4 weeks</time_frame>
    <description>As reported by participants</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of dressings used</measure>
    <time_frame>4 weeks</time_frame>
    <description>As reported by participants</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in quality of life as measured by HiSQOL</measure>
    <time_frame>Baseline, 4 weeks</time_frame>
    <description>HS quality of life (HiSQOL) has a total score ranging from 0 to 68, with higher scores indicating more severe impact on participant's quality of life</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in quality of life as measured by DLQI</measure>
    <time_frame>Baseline, 4 weeks</time_frame>
    <description>Dermatology Life Quality Index (DLQI) has a total score ranging from 0 to 30 with the lower score indicating higher health related quality of life</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">15</enrollment>
  <condition>Hidradenitis Suppurativa</condition>
  <arm_group>
    <arm_group_label>ABWG</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The participants in this group will be receiving the ABWG daily for 4 consecutive weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>antibiofilm surfactant wound gel (ABWG)</intervention_name>
    <description>ABWG is a hydro-gel applied topically using a tongue depressor</description>
    <arm_group_label>ABWG</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Adults 18 years old and older&#xD;
&#xD;
          2. Have diagnosis of HS confirmed by a dermatologist&#xD;
&#xD;
          3. Have at least one HS related tunneling wound that is at least 2 centimeters in length&#xD;
&#xD;
          4. Able to provide informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Individuals who are not yet adults&#xD;
&#xD;
          2. Women known to be pregnant&#xD;
&#xD;
          3. Prisoners&#xD;
&#xD;
          4. Subjects, who in the opinion of the PI, cannot comply with home application of the&#xD;
             treatment.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hadar Lev-Tov, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Miami</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Hadar Lev-Tov, MD</last_name>
    <phone>305-243-8485</phone>
    <email>hlevtov@med.miami.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>University of Miami</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33136</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hadar Lev-Tov, MD</last_name>
      <phone>305-243-8485</phone>
      <email>hlevtov@med.miami.edu</email>
    </contact>
    <investigator>
      <last_name>Hadar Lev-Tov, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>November 23, 2020</study_first_submitted>
  <study_first_submitted_qc>November 23, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">December 1, 2020</study_first_posted>
  <last_update_submitted>April 7, 2021</last_update_submitted>
  <last_update_submitted_qc>April 7, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 8, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Miami</investigator_affiliation>
    <investigator_full_name>Hadar Lev-Tov</investigator_full_name>
    <investigator_title>Assistant Professor</investigator_title>
  </responsible_party>
  <keyword>tunneling wound</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hidradenitis Suppurativa</mesh_term>
    <mesh_term>Hidradenitis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pulmonary Surfactants</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

